Biomedical papers, 2018 (vol. 162), issue 1

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018, 162(1):1-9 | 10.5507/bp.2017.057

Irritable bowel syndrome - from etiopathogenesis to therapy

Biljana Radovanovic-Dinica,b, Snezana Tesic-Rajkovica, Sasa Grgovc, Gordana Petrovica, Valentina Zivkovicb,d
a Clinic for Gastroenterology and Hepatology, Clinical Centre Nis, Serbia
b Faculty of Medicine, University of Nis, Serbia
c General Hospital, Leskovac, Serbia
d Institute for Treatment and Rehabilitation, Niska Banja, Serbia

Irritable bowel syndrome (IBS) is a chronic and relapsing functional gastrointestinal disorder that affects 9-23% of the population across the world. Patients with IBS are often referred to gastroenterology, undergo various investigations, take various medicines, take time off work and have a poor quality of life. The pathophysiology of IBS is not yet completely understood and seems to be multifactorial. Many pathogenetic factors, in various combinations, and not all necessarily present in each patient, can play an important role. Discomfort or abdominal pain relieived by defacation, asociated with a change in stool form, is a typical clinical manifestation of IBS. Many factors, such as emotional stress and eating, may exacerbate the symptoms. A timely diagnosis of IBS is important so that treatment which will provide adequate symptomatic relief (diarrhoea, constipation, pain and boaring) can be introduced. The diagnosis of IBS is not confirmed by a specific test or structural abnormality. It is made using criteria based on clinical symptoms such as Rome criteria, unless the symptoms are thought to be atypical. Today the Rome Criteria IV is the current gold-standard for the diagnoses of IBS. Treatment of patients with IBS requires a multidisciplinary approach. Some patients respond well to non-pharmacological treatment, while others also require pharmacological treatment. This review will provide a summary of pathophysiology, diagnostic criteria and therapies for IBS.

Keywords: irritable bowel syndrome, pathogenesis, diagnosis, Rome criteria, therapy

Received: August 8, 2017; Accepted: December 12, 2017; Prepublished online: January 18, 2018; Published: March 27, 2018


References

  1. Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:486067. Go to original source... Go to PubMed...
  2. Belcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M, Feragalli B, Togni S, Riva A, Eggenhoffner R, Giacomelli L. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2017;21(9):2249-54. Go to PubMed...
  3. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313(9):949-58. Go to original source... Go to PubMed...
  4. Soares RL. Irritable bowel syndrome: A clinical review. World J Gastroenterol 2014;20(34):12144-60. Go to original source... Go to PubMed...
  5. Noddin L, Callahan M, Lacy BE. Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations? MedGenMed 2005;7(3):17. Go to PubMed...
  6. Scalera A, Loguercio C. Focus on irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2012;16(9):1155-71. Go to PubMed...
  7. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol 2014;20(22):6759-73. Go to original source... Go to PubMed...
  8. Maxwell PR, Mendall MA, Kumar D. Irritable bowel syndrome. Lancet 1997;350(9092):1691-5. Go to original source... Go to PubMed...
  9. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014;6:71-80. Go to PubMed...
  10. Grundmann O, Yoon SL. Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for healthcare practitioners. J Gastroenterol Hepatology 2010 ;25(4):691-9. Go to original source...
  11. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [internet]. London: National Institute for Health and Care Excellence (NICE); 2015.
  12. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10(7):712-21. Go to original source... Go to PubMed...
  13. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003;52(5):663-70. Go to original source... Go to PubMed...
  14. van der Veek PP, Dusseldorp E, van Rood YR, Masclee AA. Testing a biobehavioral model of irritable bowel syndrome.Eur J Gastroenterol Hepatol 2010;22(4):412-9. Go to original source... Go to PubMed...
  15. Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 2014;20(27):8807-20. Go to PubMed...
  16. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005;100(6):1340-4. Go to original source... Go to PubMed...
  17. Park MI, Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am 2005;34(2):305-17. Go to original source... Go to PubMed...
  18. Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, De Bortoli N, Fornai M, Antonioli L, Ricchiuti A, Mumolo MG, Marchi S, Blandizzi C, Bellini M. Influence ofthe serotonintransporter 5HTTLPR polymorphism on symptomseverity in irritable bowel syndrome. PLoS One 2013;8(2):e54831. Go to original source... Go to PubMed...
  19. Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Molecular and Cellular Pediatrics 2016;3:11. Go to original source... Go to PubMed...
  20. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262-79. Go to original source... Go to PubMed...
  21. Posserud I, Ersryd A, Simrén M. Functional findings in irritable bowel syndrome. World J Gastroenterol 2006;12(18):2830-8. Go to original source... Go to PubMed...
  22. Lehrer JK. Irritable Bowel Syndrome. Medscape. Available at  http://emedicine.medscape.com/article/180389. 2017. Updated: Apr 04, 2017. 
  23. De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004;53(10):1520-35. Go to original source... Go to PubMed...
  24. Mayer EA, Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin Pharmacother 2003;4(11):2089-98. Go to original source... Go to PubMed...
  25. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments. Journal of Neurogastroenterology and Motility 2016;22(4):558-74. Go to original source... Go to PubMed...
  26. Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell MD, Olden KW, Whitehead WE. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007;56(9):1202-9. Go to original source... Go to PubMed...
  27. Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41(3):217-22. Go to original source... Go to PubMed...
  28. Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut 2002;51(1):i29-i33. Go to original source... Go to PubMed...
  29. Bonaz B, Baciu M, Papillon E, Bost R, Gueddah N, Le Bas JF, Fournet J, Segebarth C. Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Am J Gastroenterol 2002;97(3):654-61. Go to original source... Go to PubMed...
  30. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61(9):1284-90. Go to original source... Go to PubMed...
  31. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47(11):1177-85. Go to original source... Go to PubMed...
  32. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006;130(2):304-11. Go to original source... Go to PubMed...
  33. Hanevik K, Wensaas KA, Rortveit G, Eide GE, Mørch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis 2014;59(10):1394-400. Go to original source... Go to PubMed...
  34. Du Pont AW. Postinfectious irritable bowel syndrome. Clin Infect Dis 2008;46(4):594-9. Go to original source... Go to PubMed...
  35. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol 2013;6(4):295-308.  Go to original source... Go to PubMed...
  36. Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions.World Journal of Gastroenterology: WJG 2014;20(27):8859-66.
  37. Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013;15(5):323. Go to original source... Go to PubMed...
  38. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004;53(10):1459-64. Go to original source... Go to PubMed...
  39. Elli L, Branchi F, Tomba C, Villalta D, Norsa L, Ferretti F, Roncoroni L, Bardella MT. Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. World Journal of Gastroenterology: WJG 2015;21(23):7110-9. Go to original source...
  40. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145(2):320-8. Go to original source... Go to PubMed...
  41. Seo AY, Kim N, Oh DH. Abdominal Bloating: Pathophysiology and Treatment.Journal of Neurogastroenterology and Motility 2013;19(4):433-53. Go to original source... Go to PubMed...
  42. Layer P, Keller J, Loeffler H, Kreiss A. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Therapeutics and Clinical Risk Management 2007;3(1):107-18. Go to original source... Go to PubMed...
  43. Bonavita V, De Simone R. Towards a definition of comorbidity in the light of clinical complexity. Neurol Sci 2008;29(1):S99-102. Go to original source... Go to PubMed...
  44. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119(3):654-60. Go to original source... Go to PubMed...
  45. Hungin AP, Molloy-Bland M, Claes R, Heidelbaugh J, Cayley WE Jr, Muris J, Seifert B, Rubin G, de Wit N. Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - a Rome Foundation working team report. Aliment Pharmacol Ther 2014;40(10):1133-45. Go to original source... Go to PubMed...
  46. Soubieres A, Wilson P, Poullis A, Wilkins J, Rance M. Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service. Frontline Gastroenterology 2015;6:246-51. Go to original source... Go to PubMed...
  47. Sunderland R. Irritable bowel syndrome in adults: symptoms, treatment and management. Nurs Stand 2017;31(26):52-63. Go to PubMed...
  48. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. 4 Identification of subgroups of functional bowel disorders. Gastroenterology International 1990;3(4):159-72.
  49. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Miller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999;45(2):II43-7.
  50. Drossman DA. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology 2006;130(5):1377-90. Go to original source... Go to PubMed...
  51. Schmulson MJ, Drossman DA. What Is New in Rome IV. Neurogastroenterol Motil 2017;23(2):151-63. Go to original source...
  52. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology 2016;150(6):1393-407.  Go to original source... Go to PubMed...
  53. Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep 2017;19(4):15. Go to original source... Go to PubMed...
  54. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol 2011;106(5):915-22. Go to original source... Go to PubMed...
  55. Iovino P, Bucci C, Tremolaterra F, Santonicola A, Chiarioni G. Bloating and functional gastro-intestinal disorders: Where are we and where are we going?World Journal of Gastroenterology: WJG 2014;20(39):14407-19. Go to original source...
  56. Spiller R, Aziz Q, Creed F Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56(12):1770-98. Go to original source... Go to PubMed...
  57. Volta U, Pinto-Sanchez MI, Boschetti E, Caio G, De Giorgio R, Verdu EF. Dietary Triggers in Irritable Bowel Syndrome: Is There a Role for Gluten? Journal of Neurogastroenterology and Motility 2016;22(4):547-57. Go to original source... Go to PubMed...
  58. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W,Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Nonceliac gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013;5(10):3839-53. Go to original source... Go to PubMed...
  59. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2012;8(11):739-45. Go to PubMed...
  60. Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ.Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19(3):245-51. Go to original source... Go to PubMed...
  61. Anastasi JK, Capili B, Chang M. Managing irritable bowel syndrome. Am J Nurs 2013;113(7):42-52. Go to original source... Go to PubMed...
  62. Fukudo S, Hongo M, Kaneko H, Takano M, Ueno R. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol 2015;13(2):294-301. Go to original source... Go to PubMed...
  63. Sarosiek I, Bashashati M, Alvarez A, Hall M, Shankar N, Gomez Y, McCallum RW, Sarosiek J. Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation. Am J Med Sci 2016;352(3):231-8. Go to original source... Go to PubMed...
  64. Videlock EJ, Cheng V, Cremonini F. Effects of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation: A Meta-analysis. Clin Gastroenterol Hepatol 2013;11(9):1084-92. Go to original source... Go to PubMed...
  65. Rao SS, Quigley EM, Shiff SJ, Lavins BJ, Kurtz CB, MacDougall JE, Currie MG, Johnston JM. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol 2014;12(4):616-23. Go to original source... Go to PubMed...
  66. Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1-35. Go to original source... Go to PubMed...
  67. Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S, Amercian Gastroenterological Association. American Gastroenterological Association Institute Guideline on the pharmacological management of Irritable bowel syndrome. Gastroenterology 2014;147(5):1146-8. Go to original source... Go to PubMed...
  68. Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147(5):1149-72. Go to original source... Go to PubMed...
  69. Gunn MC, Cavin AA, Mansfield JC. Management of irritable bowel syndrome. Postgrad Med J 2003;79:154-8. Go to original source... Go to PubMed...
  70. Özdener AE, Rivkin A. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Drug Design, Development and Therapy 2017;11:2827-40. Go to original source... Go to PubMed...
  71. Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. The American Journal of Gastroenterology 2017;112(2):365-374. Go to original source... Go to PubMed...
  72. Rivkin A, Rybalov S. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline. Pharmacotherapy 2016;36(3):300-16. Go to original source... Go to PubMed...
  73. Foxx-Orenstein AE. New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol 2016;9(3):354-75. Go to original source... Go to PubMed...
  74. Hadley SK, Gaarder SM. Treatment of Irritable Bowel Syndrome. Am Fam Physician 2005;72(12):2501-8. Go to PubMed...
  75. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ 2012;345:e5836. Go to original source... Go to PubMed...
  76. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 2014;20(27):8796-806. Go to PubMed...
  77. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59(3):325-32. Go to original source... Go to PubMed...
  78. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 2014;146(6):1554-63. Go to original source... Go to PubMed...
  79. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Moayyedi P. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109(10):1547-61. Go to original source... Go to PubMed...
  80. Pinn DM, Aroniadis OC, Brandt LJ. Is Fecal Microbiota Transplantation the Answer for Irritable Bowel Syndrome? A Single-Center Experience. Am J Gastroenterol 2014;109(11):1831-2.
  81. Borody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004;38(6):475-83. Go to original source... Go to PubMed...
  82. Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, Wei Y, Chen Q, Zhu W, Li J, Li N. Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study. J Clin Gastroenterol 2016;50(10):865-70. Go to original source... Go to PubMed...
  83. Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus 2016;5(1):1130. Go to original source... Go to PubMed...
  84. Hadley SK, Gaarder SM. Treatment of Irritable bowel syndrome. Am Fam Physician 2005;72(12):2501-6. Go to PubMed...
  85. Lucak S, Chang L, Halpert A, Harris LA. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.Therap Adv Gastroenterol 2017;10(2):253-75. Go to original source... Go to PubMed...
  86. Owyang C. Irritable bowel syndrome. In; T Yamada (eds). Textbook of Gastroenterology, 5th edn. Philadelphia: Lippincott Williams and Wilkins; 2009;pp.1536-74.
  87. Fukudo S, Kinoshita Y, Okumura T, Ida M, Hayashi K, Akiho H, Nakashima Y, Haruma K. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol 2016;51(9):874-82. Go to original source... Go to PubMed...
  88. Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017;23(36):6593-27. Go to original source... Go to PubMed...
  89. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58(3):367-78. Go to original source... Go to PubMed...
  90. Gorard DA, Libby GW, Farthing MJ. Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome. Dig Dis Sci 1995;40(1):86-95. Go to original source... Go to PubMed...
  91. Sinagra E, Romano C, Cottone M. Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome. Gastroenterology Research and Practice 2012;2012:486067. Go to original source... Go to PubMed...